News & Updates
Filter by Specialty:
HK data: LAI antipsychotics superior to oral antipsychotics in older patients with schizophrenia
Long-acting injectable (LAI) antipsychotics are associated with lower risks of disease relapse and mortality than oral antipsychotics in older patients with schizophrenia, a population-based study in Hong Kong has shown.
HK data: LAI antipsychotics superior to oral antipsychotics in older patients with schizophrenia
28 Oct 2025
Soft drinks may fuel depression via gut microbiome
Consumption of soft drinks predicts major depressive disorder (MDD) diagnosis and symptom severity in women through gut microbiota alterations, a cohort study has shown.
Soft drinks may fuel depression via gut microbiome
28 Oct 2025
Enzalutamide-ADT a win for biochemically recurrent prostate cancer
In the final overall survival (OS) analysis of the phase III EMBARK trial, the combination of enzalutamide and androgen deprivation therapy (ADT; leuprolide acetate) delivers a significant OS benefit in men with high-risk biochemically recurrent (hrBCR) prostate cancer without evidence of metastases on conventional imaging.
Enzalutamide-ADT a win for biochemically recurrent prostate cancer
27 Oct 2025
ALEX final OS analysis: Alectinib superior to crizotinib in 1L ALK+ NSCLC
Final overall survival (OS) data analysis from the phase III ALEX study presented at ESMO 2025 indicates alectinib is superior to crizotinib in patients with previously untreated ALK-positive (ALK+) non-small-cell lung cancer (NSCLC).